330 related articles for article (PubMed ID: 28391355)
1. Comparison between hypersensitivity reactions to cycles of modified FOLFOX6 and XELOX therapies in patients with colorectal cancer.
Ohta H; Hayashi T; Murai S; Shiouchi H; Ando Y; Kumazawa S; Ito K; Ikeda Y; Matsuoka H; Maeda K; Kawada K; Yasuda K; Yamada S
Cancer Chemother Pharmacol; 2017 May; 79(5):1021-1029. PubMed ID: 28391355
[TBL] [Abstract][Full Text] [Related]
2. Safety of mFOLFOX6/XELOX as adjuvant chemotherapy after curative resection of stage III colon cancer: phase II clinical study (The FACOS study).
Kosugi C; Koda K; Ishibashi K; Yoshimatsu K; Tanaka S; Kato R; Kato H; Oya M; Narushima K; Mori M; Shuto K; Ishida H
Int J Colorectal Dis; 2018 Jun; 33(6):809-817. PubMed ID: 29484450
[TBL] [Abstract][Full Text] [Related]
3. Comparison of first-line bevacizumab in combination with mFOLFOX6 or XELOX in metastatic colorectal cancer.
Vedat Bayoglu I; Yildiz I; Varol U; Cokmert S; Kucukzeybek Y; Alacacioglu A; Demir L; Dirican A; Akyol M; Yildiz Y; Oktay Tarhan M
J BUON; 2015; 20(2):460-7. PubMed ID: 26011336
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for oxaliplatin-induced hypersensitivity reactions in Japanese patients with advanced colorectal cancer.
Seki K; Senzaki K; Tsuduki Y; Ioroi T; Fujii M; Yamauchi H; Shiraishi Y; Nakata I; Nishiguchi K; Matsubayashi T; Takakubo Y; Okamura N; Yamamori M; Tamura T; Sakaeda T
Int J Med Sci; 2011 Mar; 8(3):210-5. PubMed ID: 21448307
[TBL] [Abstract][Full Text] [Related]
5. Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients.
Argyriou AA; Velasco R; Briani C; Cavaletti G; Bruna J; Alberti P; Cacciavillani M; Lonardi S; Santos C; Cortinovis D; Cazzaniga M; Kalofonos HP
Ann Oncol; 2012 Dec; 23(12):3116-3122. PubMed ID: 22865779
[TBL] [Abstract][Full Text] [Related]
6. Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study.
Santini D; Vincenzi B; Schiavon G; Di Seri M; Virzí V; Spalletta B; Caricato M; Coppola R; Tonini G
Cancer Chemother Pharmacol; 2007 Apr; 59(5):613-20. PubMed ID: 16944151
[TBL] [Abstract][Full Text] [Related]
7. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer.
Ducreux M; Bennouna J; Hebbar M; Ychou M; Lledo G; Conroy T; Adenis A; Faroux R; Rebischung C; Bergougnoux L; Kockler L; Douillard JY;
Int J Cancer; 2011 Feb; 128(3):682-90. PubMed ID: 20473862
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
Cassidy J; Clarke S; Díaz-Rubio E; Scheithauer W; Figer A; Wong R; Koski S; Lichinitser M; Yang TS; Rivera F; Couture F; Sirzén F; Saltz L
J Clin Oncol; 2008 Apr; 26(12):2006-12. PubMed ID: 18421053
[TBL] [Abstract][Full Text] [Related]
9. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.
Cassidy J; Tabernero J; Twelves C; Brunet R; Butts C; Conroy T; Debraud F; Figer A; Grossmann J; Sawada N; Schöffski P; Sobrero A; Van Cutsem E; Díaz-Rubio E
J Clin Oncol; 2004 Jun; 22(11):2084-91. PubMed ID: 15169795
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy and toxicity analysis of XELOX and FOLFOX4 regimens as adjuvant chemotherapy for stage III colorectal cancer].
Lu GC; Fang F; Li DC
Zhonghua Zhong Liu Za Zhi; 2010 Feb; 32(2):152-5. PubMed ID: 20403249
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of adjuvant XELOX and FOLFOX6 chemotherapy after D2 dissection for gastric cancer.
Wu Y; Wei ZW; He YL; Schwarz RE; Smith DD; Xia GK; Zhang CH
World J Gastroenterol; 2013 Jun; 19(21):3309-15. PubMed ID: 23745033
[TBL] [Abstract][Full Text] [Related]
12. [Clinical observation of XELOX (Capecitabine puls Oxaliplatin): an adjuvant chemotherapy regimen used in stage III colorectal cancer].
Diao C; Cheng RC; Zhang JM; Wei XP; Su YJ; Liu QY; Xu JB
Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):147-50. PubMed ID: 18646702
[TBL] [Abstract][Full Text] [Related]
13. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients.
Schmoll HJ; Cartwright T; Tabernero J; Nowacki MP; Figer A; Maroun J; Price T; Lim R; Van Cutsem E; Park YS; McKendrick J; Topham C; Soler-Gonzalez G; de Braud F; Hill M; Sirzén F; Haller DG
J Clin Oncol; 2007 Jan; 25(1):102-9. PubMed ID: 17194911
[TBL] [Abstract][Full Text] [Related]
14. [Tolerability of XELOX in postoperative adjuvant chemotherapy for colorectal cancer].
Matsuda C; Danno K; Miyazaki S; Fujitani K; Kubota M; Kawada J; Takagi M; Fukui A; Iwase K; Tanaka Y
Gan To Kagaku Ryoho; 2014 Jun; 41(6):743-7. PubMed ID: 25129086
[TBL] [Abstract][Full Text] [Related]
15. Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study.
Soda H; Maeda H; Hasegawa J; Takahashi T; Hazama S; Fukunaga M; Kono E; Kotaka M; Sakamoto J; Nagata N; Oba K; Mishima H
BMC Cancer; 2015 Oct; 15():695. PubMed ID: 26467662
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study.
Waddell T; Gollins S; Soe W; Valle J; Allen J; Bentley D; Morris J; Lloyd A; Swindell R; Taylor MB; Saunders MP
Cancer Chemother Pharmacol; 2011 May; 67(5):1111-7. PubMed ID: 20676676
[TBL] [Abstract][Full Text] [Related]
17. Two Doses of oxaliplatin with capecitabine (XELOX) in metastatic colorectal cancer.
Moreno-Solórzano I; Ibeas-Rollan R; Monzó-Planella M; Moreno-Solórzano J; Martínez-Ródenas F; Pou-Sanchis E; Hernández-Borlan R; Navarro-Vigo M; Ortigosa-Rodríguez S; Gel-Moreno B
Clin Colorectal Cancer; 2007 Sep; 6(9):634-40. PubMed ID: 17945035
[TBL] [Abstract][Full Text] [Related]
18. Feasibility of Capecitabine and Oxaliplatin Combination Chemotherapy Without Central Venous Access Device in Patients With Stage III Colorectal Cancer.
Lapeyre-Prost A; Hug de Larauze M; Chibaudel B; Garcia ML; Guering-Meyer V; Bouché O; Boucher E; Ychou M; Dauba J; Obled S; Lièvre A; Malka D; Faroux R; Bonnet I; Taieb J; André T;
Clin Colorectal Cancer; 2016 Sep; 15(3):250-6. PubMed ID: 26752558
[TBL] [Abstract][Full Text] [Related]
19. High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin.
Kidera Y; Satoh T; Ueda S; Okamoto W; Okamoto I; Fumita S; Yonesaka K; Hayashi H; Makimura C; Okamoto K; Kiyota H; Tsurutani J; Miyazaki M; Yoshinaga M; Fujiwara K; Yamazoe Y; Moriyama K; Tsubaki M; Chiba Y; Nishida S; Nakagawa K
Int J Clin Oncol; 2011 Jun; 16(3):244-9. PubMed ID: 21243395
[TBL] [Abstract][Full Text] [Related]
20. XELOX versus FOLFOX6 as an adjuvant treatment in colorectal cancer: an economic analysis.
Maniadakis N; Fragoulakis V; Pectasides D; Fountzilas G
Curr Med Res Opin; 2009 Mar; 25(3):797-805. PubMed ID: 19215190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
